Abstract
This article was completed during the final stages of the Pfizer take-over of Pharmacia. Unlike earlier company profiles, this analysis has attempted to identify any likely synergies for their combined research programme and any facets that Pharmacia uniquely brings to the merged company. A newly-introduced patent analysis tool, the database of all pharmaceutical inventions (DOLPHIN) from Current Patents Ltd [201], has been used as the primary research method. DOLPHIN draws heavily upon data from the international patent database published by the European Patent Office (INPADOC) but presents it in a more visual manner. Some comparisons between the methodology of earlier patent surveys and the new features allowed by DOLPHIN have been considered during this review.